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Background: High-frequency airway clearance (HFCWC) assist devices generate either positive or negative
trans-respiratory pressure excursions to produce high-frequency, small-volume oscillations in the airways.
HFCWC can lead to changes in volume of 15–57 ml and in flow up to 1.6 L/s, which generate minimal coughing to
mobilize secretions. The typical treatment lasts 20–30 minutes, and consists of short periods of compression at
different frequencies, separated by coughing.
The aim of this study was to find the more efficacious treatment in patients with bronchiectasis: traditional
techniques of chest physiotherapy (CPT) versus high frequency oscillation of the chest wall in patients with
bronchiectasis.
Methods: 37 patients were enrolled. Seven of them were excluded. Computer randomization divided the patients
into three groups:
– 10 patients treated with HFCWO by using the VestW Airway Clearance System;
– 10 patients treated with traditional techniques of air way clearance (PEP bottle, PEP mask, ELTGOL, vibratory
positive expiratory pressure);
– 10 patients received medical therapy only (control group).
To be eligible for enrollment, participants had to be between 18 and 85 years old and have a diagnosis of
bronchiectasis, confirmed on high resolution computed tomography. Exclusion criteria: lack of informed consent,
signs of exacerbation, cystic fibrosis. Before the treatment, each patient had blood tests, sputum volume and cell
count, pulmonary function tests and on the quality of life inventories (MMRC, CAT, BCSS). The results were
processed through the covariance analysis, performed with the R-Project statistical program. It has been considered
a positive result p <005.
Results: Both treatments (traditional CPT and HFCWO) showed a significant improvement in some biochemical and
functional respiratory tests as well as in the quality of life compared to the control group. The use of HFCWO
compared to CPT also produced a significant improvement in blood inflammation parameter C-RP (p ≤0.019),
parameters of lung functionality associated with bronchial obstruction (FVC, FEV1) (p ≤0.006 and p ≤0.001), and in
the dyspnea. Improvement in quality of life scales was noted. (BCSS, CAT) (both p ≤0.001). No significant changes
of total cell counts in sputum samples were observed in the two groups. In the HFCWO group a significant
reduction of neutrophils percentage (p≤0.002) and a significant increase of macrophages percentage (p ≤0.012).
(Continued on next page)* Correspondence: antonello.nicolini@fastwebnet.it
1Respiratory Diseases Unit,General Hospital of Sestri Levante, Genoa, Italy
Full list of author information is available at the end of the article
© 2013 Nicolini et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Nicolini et al. BMC Pulmonary Medicine 2013, 13:21 Page 2 of 8
http://www.biomedcentral.com/1471-2466/13/21(Continued from previous page)
Conclusions: The HFCWO technique provides an improvement both in pulmonary function and quality of life
related parameters in patients with chronic hypersecretive disease. Since those patients need daily airway clearance,
this treatment should be included among the principal options in chest physiotherapy. The study was registered as
ChiCTR-TRC-12002134 at www.chictr.org.
Keywords: Bronchiectasis, High frequency chest wall oscillation, Chest physiotherapy, Lung function, Sputum cell
count, Dyspnea scalesBackground
Bronchiectasis is defined as an irreversible dilatation and
destruction of the bronchi [1] with a reduction in clearance
of secrections (and particularly in the expiratory airflow)
[2]. This disease can lead to recurrent lower respiratory
tract infections and worsening pulmonary function, with
increased morbidity and mortality [2-5]. The incidence and
the prevalence of bronchiectasis is not known, but its diag-
nosis has increased mainly due to the more frequent use of
high-resolution computed tomography [2,6]. Bronchiec-
tasis is usually associated with chronic cough, increasing
secretions, and recurrent airway and pulmonary infections
[6]. The fundamental aspects in these patients are the colo-
nizations and infection of the bronchial mucous by poten-
tially pathogenic microorganisms such as Pseudomonas
Aeruginosa, Burkholderia cepacia and others. This chronic
process results in the destruction and dilatation of the
bronchial tree that is the characteristic of the disease [7].
The goals of bronchiectasis treatment are to reduce the
number of exacerbations and infections and to improve
patient quality of life by reducing airway inflammation and
mobilizing secretions [6,8,9]. Therapies showing to be ef-
fective in cystic fibrosis are often provided to patients with
bronchiectasis,without definitive evidence of benefit. In
recent years, there has been increased interest in validating
and developing new therapies for patients without cystic
fibrosis [10]. These include inhaled antibiotics (tobramycin,
aztreonam, ciprofloxacin, colistin, amikacin) [10], hyper-
osmolar agents (hypertonic saline solution, dry powder
mannitol) [10,11], anti-inflammatory agents (macrolides,
corticosteroids) [7,12], bronchodilators (salbutamol) [13],
chest physiotherapy, physical exercise and nutritional treat-
ment [7,14-16]. In the field of chest physiotherapy several
secretion management techniques have been proposed:
they include modified postural drainage [17], assisted
cough [17], active cycle of breathing techniques [17,18],
oscillatory positive-expiratory pressure devices [17,18] and
intrapulmonary percussive ventilation [6]. Although the
mucous clearance is recommended in bronchiectasis,
there are no definitive studies or guidelines on the pref-
erence or superiority of one technique versus the others
[6,19]. High frequency chest wall oscillation (HFCWO)
is widely used in the USA where is considered standardcare in cystic fibrosis (CF) [20,21]. It has recently been
introduced to UK and Europe and has been used in
several other pulmonary diseases, different from CF like
chronic obstructive pulmonary disease [22] or exacerba-
tions of chronic obstructive pulmonary disease or bron-
chial asthma [23]. To our knowledge there have been no
trials of HFCWO in patients with non-CF bronchiec-
tasis. The aim of the study was to compare the efficacy,
the safety of HFCWO with our standard traditional
chest physiotherapy (CPT) in patients with non-CF
bronchiectasis.Methods
37 Adults (aged 18 years and older) with a chest com-
puted tomography confirmed diagnosis of bronchiectasis
were admitted to the study in the Respiratory Disease
Unit of General Hospital of Sestri Levante,Italy from
April to June 2012. The inclusion criteria were:
– Daily sputum volume ≥ 20 ml daily at least 3
consecutive days [22]
– Clinical stability: no need for medication changes a
week prior to enrollment
– Normal gas exchange: ph ≥7.35 during spontaneous
breathing, with or without supplemental oxygen
– No major cardiac arrhythmias or hemodynamic
instability.
The exclusion criteria were cystic fibrosis, tracheos-
tomy, non-invasive ventilation, inability to perform
forced expiratory maneuvers, recent episode of signifi-
cant hemoptysis, or pneumothorax in the six months
preceding enrollment. The drop-out criteria were with-
drawal of patient consent, severe clinical worsening,
chest radiograph changes and occurrence of any of the
exclusion criteria.
The study was carried out according to the rules of
the declaration of Helsinki and approved by Ethics
committee of ASL 4 Chiavarese all patients provided
written informed consent before beginning the study.
The study was registered as Chi CTR-TRC-12002134
at www.chictr.org.
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Every patient was assigned following a computed
randomized list to High frequency chest wall oscillation
(HFCWO) or to chest physiotherapy (CPT) or to med-
ical therapy only (control group) (Figure 1). CPT secre-
tion clearance sessions lasted 45 minutes per session;
HFCWO lasted 30 minutes per session. Both treatments
were given twice daily (morning and late afternoon).The
duration of each treatment was fifteen days: the treat-
ment was administered five days per week. High fre-
quency chest wall oscillation (HFCWO). HFCWO was
provided with the VestW Airway Clearance System (Hill-
Rom, Batesville, Indiana, USA).The Vest system consists
of an inflatable vest, which is worn over the torso and
an air pulse generator that delivers the oscillating air
pulses to the vest via a connecting air hose. The patient
was in upright sitting position and the Vest air pulse
generator was set to an optimum oscillating frequency
of 13–15 Hz based on individual patient tolerance and a
pressure setting of 2–5 cm H2O to achieve a tight but
comfortable snug fit [22]. Every session lasted 30 mi-
nutes and every patient had a treatment twice per day
(morning and late afternoon). Chest Physiotherapy (CPT)
consisted of a group of respiratory physiotherapy tech-
niques like, slow expiratory with glottis opened in late-
ral position (ELTGOL) [24], positive expiratory pressure
(PEP) mask [25] or PEP bottle [26] and vibratory positive
expiratory pressure therapy system [27] (Acapella choice,
Smiths Medical, England). Every session lasted 45 minutesHFCWO    HIGH FREQUENCY CHEST WALL OSCILLATION
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Figure 1 Patients flow.and every patient had a treatment twice per day (morning
and late afternoon).Measurements
Primary outcome measures included dyspnea, cough,
and sputum scales, as well as daily life activity evalua-
tions. Secondary outcome measures were respiratory
function testing and, hematological examinations, and
sputum cell count. Dyspnea, cough and sputum and
daily life activity was measured with the Breathlessness,
Cough, and Sputum Scale (BCSS) [28], COPD Assess-
ment Test (CAT) [29,30] and Modified Medical Re-
search Council (MMRC) Dyspnea Scale. Sputum sample
for analysis was defined as that containing expectorated
material with cellular viability greater than 50% and con-
tamination by oropharyngeal squamous cell cells lower
than 20%, as well as being of a quantity sufficient
for differential counts of 400 cells [31,32]. Sputum
collection was made the day of the starting of the treat-
ment and the day of the last treatment. The patients
were instructed by the physiotherapists or by the nurses
to expectorate into the sputum cups during the entire
duration of the treatment and to continue expectoring
if the patient felt the need to cough. All sputum
produced over the 60-minute period was collected [33].
Pulmonary function testing was performed with a
computerized body plethysmography (VMAX 20 PFT
Sensor Medics, Yorba Linda, CA,US), according to theTable 1 Baseline characteristics of the patients
Control group HFWCO group CPT group






Mean SD Mean SD Mean SD
AGE(years) 71.9 7.46 74.6 4.69 73.9 3.66
FVC°(ml) 2125 898.9 2545 820 2427.5 813.7
FEV1°°(ml) 1016 628.9 1509 625.5 1739 672.9
Tiffeneau Index 46.5 14.1 58.4 13.8 68.7 13.3
TLC°°°(ml) 5593 2013 5993 2407.2 5931 1546.8
RV°°°°(ml) 3423 2047.4 3161 1106.5 3353 2320.6
paO2(mmHg) 66.2 4.9 70.9 8.6 76.3 12.3
paCO2(mmHg) 42.4 1.4 42.5 4.6 37.4 6.6
MIP*(cmH2O) 50.5 10.4 61 13 54.8 16.7
MEP**(cmH2O) 65 12.6 66.6 17.7 65 23.2
MMRC*** 2.2 0.4 2.1 0.7 2.3 1.3
CAT**** 17.9 8.5 23.9 6.3 17.7 8.3
BCSS***** 6.2 2.4 6.8 2.8 4.9 2.8
°Forced vital capacity * Maximal Inspiratory Pressure.
°°Forced expiratory volume 1 minute ** Maximal Expiratory Pressure.
°°° Total lung capacity *** Modified Medical Research Scale.
°°°° Residual volume **** COPD Assessment Test.
***** Breathlessness, Cough and Sputum Scale.
Figure 2 Dot-plot that shows BCSS score and CAT score
change-values before and after treatment in HFCWO and
CPT groups.
Figure 3 Dop-plot that shows FVC and FEV1 change values (ml)
before and after treatment in HFCWO and CPT groups.
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of the patients are shown in Table 1.
Statistical analysis
Clinical data were expressed as count and mean and
standard deviation. We calculated the difference bet-
ween the two treatments (HFCWO and CPT) and control
group using univariate (covariance) analysis. Subse-
quently, the difference between the two treatments
(HFCWO and CPT) was analyzed using covariance ana-
lysis; p≤0.05 was considered statistically significant. Data




There were 52 patients admitted during the study period:
37 patients were screened and 30 were enrolled (9 men
and 21 women) (Table 1). The reasons for exclusion were:
recent episode of significant hemoptysis (1 patient),
episode of pneumothorax in the six months preceding
enrollment (1 patient), inability to perform forced expira-
tory maneuvers (2 patients), refusal (3 patients). All the 20
patients (7 males and 13 females) assigned to airway clear-
ance sessions completed their sessions. None of the
patients enrolled withdrew from the study because of
discomfort with HFCWO device or CPT. None had exa-
cerbations. All were clinically stable and able to cough
spontaneously. Moreover, the patients in the control
group did not have exacerbations: in three cases they
presented an average increase in sputum volume of 10 ml
at the end of the study.
Measurements
Breathlessnes and life quality scales Both treatment
showed an increase in all the three test used for the
assessment of dyspnea and quality of life (BCSS, MMRC,
CAT) respect to control group. HFCWO showed a
significant improvement in BCSS (p ≤0.001) and CAT
(p ≤0.001) than CPT (Figure 2).
Respiratory function and laboratory measurements
Both groups (CPT and HFCWO) presented a significant
improvement in pulmonary function tests (FVC and
FEV1) in comparison with control group. Moreover, the
HFCWO group showed a significant increasing of FVC
and FEV1 after treatment (p ≤0.006 and p≤0.001)
(Figure 3). Among biochemical laboratory blood measure-
ments the HFCWO group showed a significant reduction
of C-reactive protein compared to CPT group (p ≤0.019).
Sputum volume Both HFCWO and CPT increased
after treatment the sputum production: from 62.5±18.9
ml at admission to 70.0± 21.1 in the CPT group and
Table 2 Biochemical, lung function, and QOL value before and after in the three groups
Control group (Ctrl) CPT treatment HFCWO treatment Difference between after and before
difference difference difference CPT HFCWO HFCWO
After-before After-before After-before vs Ctrl vs Ctrl vs CPT
Mean SD Mean SD Mean SD P-value (covariance analysis)
WC (103 cell) 957.0 915.7 407.0 2211.2 −673.8 1093.6 0.42 0.02 0.123
RC (106 cell) −82.0 62.3 26.0 164.7 73.0 202.5 0.13 0.03 0.503
Neutr % 5.4 9.2 1.2 4.2 −4.0 8.5 0.23 0.01 0.136
Lymph % −1.4 3.7 −1.4 2.8 0.6 7.2 0.99 0.37 0.377
FVC (ml) −37.0 35.0 54.5 153.7 192.1 80.9 0.06 0.001 0.006
FEV1 (ml) −21.0 30.7 −94.0 128.3 135.5 93.4 0.09 0.001 0.001
Tiff.Ind. −0.6 1.3 −0.6 3.5 3.1 6.7 0.99 0.07 0.072
TLC (ml) 46.0 95.6 −88.0 312.4 −657.0 1088.9 0.65 0.02 0.063
RV (ml) 65.0 58.5 −145.0 327.8 −580.0 1118.1 0.49 0.04 0.160
Mip (cmH2O) −4.1 2.5 2.1 13.2 9.8 10.1 0.16 0.003 0.088
Mep (cmH2O) −8.3 3.9 2.4 23.6 6.5 7.2 0.10 0.03 0.530
paO2 (mmHg) −1.4 3.5 0.8 9.5 1.7 8.8 0.54 0.38 0.786
paCO2 (mmHg) 0.9 1.8 1.1 2.5 −0.9 2.7 0.82 0.10 0.066
ph −0.004 0.010 0.001 0.023 0.016 0.028 0.59 0.049 0.143
BCSS 3.1 1.4 0.2 1.8 −2.7 1.8 0.001 0.001 0.001
MMRC 1.0 0.8 −0.5 1.1 −0.7 0.8 0.001 0.001 0.629
CAT 9.9 3.6 0.4 6.8 −8.0 4.0 0.001 0.001 0.001
C-R Prot. 1.3 1.1 0.0 0.9 −1.0 0.8 0.01 0.001 0.019
The table displays covariate-unadjusted mean levels.
WC White cells - RC Red cells - FVC Forced vital capacity - FEV1 Forced Expiratory volume 1 sec - Tiff Ind Tiffeneau Index - TLC Total lung capacity - RV residual
volume - MIP Maximal inspiratory pressure - MEP Maximal expiratory pressure.
BCSS Breathlessness, Cough, Sputum, Scale - MMRC Modified Medical Research Council Dyspnea Scale - CAT COPD assessment test -C-R prot C-reactive protein
Ctrl Control group CPT Chest physiotherapy group HFCWO high frequency chest wall oscillation group.
QOL Quality of life.
Table 3 Sputum cytological changes before and after in the three groups
Control group (Ctrl) CPT treatment HFCWO treatment Difference between after and before
Before After Before After Before After CPT HFCWO HFCWO
vs Ctrl vs Ctrl vs CPT
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD P-value (covariance analysis)
TCCx 106/mg 9891 1797.3 10517 2514.9 9.636 3.181 8.490. 2.771 9.671 2.136 7.225 1.186 0.001 0.001 0.096
Neutroph % 70.54 5.5 78.09 6.8 65.3 10.1 62.0 9.9 72.5 9.2 59.9 10.1 0.001 0.001 0.002
Lymphoc % 9.11 3.6 7.17 2.7 11.3 4.8 13.5 3.9 10.2 5.2 11.9 4.9 0.001 0.001 0.548
Eosin % 1.09 0.46 0.97 0.44 0.9 0.4 0.7 0.4 0.6 0.2 0.6 0.1 0.7 0.5 0.333
Macroph % 37.2 7.8 32.2 10.8 26.9 8.5 31.2 7.5 19.9 11.1 35.6 15.2 0.03 0.001 0.012
Sputum (ml) 74.0 10.7 77.0 10.6 70.0 21.1 62.5 18.9 72.5 23.9 52.0 16.9 0.04 0.001 0.01






HFCWO High frequency chest wall oscillation.
Ctrl Control group.
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group. There was a significant difference in HFCWO
group, where the treatment produced a greater increase of
sputum volume at the end of treatment (p≥ 0.011). All the
results of the measurements are reported in Table 2. The
table displays covariate-unadjusted mean levels.
Sputum cellularity No significant changes of total cell
counts in sputum samples were observed in the two
groups. In the HFCWO group a significant reduction
of neutrophils percentage (p ≤0.002) and a significant
increasing of macrophages percentage (p ≤0.012) was
observed. All the results of the sputum cellularity mea-
surements are reported in Table 3. The table displays
covariate-unadjusted mean levels.
Discussion
Techniques for augmenting the normal muco-ciliary and
cough clearance mechanisms of the lungs are not new,
but in recent years several techniques have been devel-
oped which are effective and comfortable; these tech-
niques can be used without an assistant in the majority
of adolescents and adults [35]. HFCWO has been one of
the most studied techniques in the more recent years
and it has been used in many circumstances such as
thoracic trauma [36], neuromuscular diseases, chronic
obstructive pulmonary disease [22,23,37,38], bronchial
asthma [23], and cystic fibrosis [38-47]. In chronic ob-
structive pulmonary diseases HFCWO produces im-
provements in gas mixing and homogenization of
alveolar ventilation for previously closed or under venti-
lated lung units [37,44]. HFCWO has been shown to de-
crease functional residual capacity (FRC) in subject with
obstructive lung disease [37,39]:this could explain the
improvement of FVC we have observed. Moreover, high
frequency chest wall oscillation delivers an intermittent
flow of air into the jacket which rapidly compresses and
releases the chest wall at a variety of frequencies. An
oscillation in airflow within the airways is achieved.
HFCWO has been shown to augment central and per-
ipheral mucus clearance [21]. Only one study reported
an improvement in FEV1 in the longer term using [46],
and few trials have compared HFCWO with traditional
chest physiotherapy in cystic fibrotic (CF) patients with
favorable results for HFCWO [21,41,46]. The effects of
HFCWO on sputum production as well as lung function
is in dispute. Compared with PEP, there was no dif-
ference in either lung function or sputum production
[41,47]. When compared with oscillating PEP, one study
showed a benefit in terms of sputum production but did
not show differences in lung function [34,41,48]. A
recently published study on hypersecretive COPD with
recurrent exacerbations showed that the treatment with
HFCWO led to improvement in lung function, quality oflife, and reduction of symptoms, but not in sputum pro-
duction [22]. An important limitation of most HFCWO
studies is the short number of days of treatment. This
makes it difficult to evaluate some outcomes like lung
function or quality of life, which need much more time
to change. None of the previous studies investigated
sputum cellularity and its changes after airways clear-
ance treatment. If we consider already published defini-
tions used in the analysis of sputum cellularity (32, 33,
49) all the patients enrolled in the two groups (HFCWO
and CPT) presented at starting a total cell count sug-
gesting in all the patient the absence of infection. The
reduction of percentage of neutrophils and the increase
of percentage of macrophage could suggest a modulation
of HFCWO in inflammatory cells (greater than CPT),
but these data must be validated with further studies.
The significance of this observation is not known.
Limitations
We are aware of the limitations of our study. The amount
of daily sputum volume was not reported; we collected
sputum at before the first treatment and at the end of the
last (when also performed cytological counts). We do not
have concerning information about the daily variations in
sputum volume. Moreover, this medium-term study does
not allows us to provide information about the efficacy
and acceptability of the device in the long-term.
Conclusions
Our study showed that HFCWO produced an improve-
ment in several lung function parameters compared to
traditional chest physiotherapy. Long-term study are
needed, not only to establish the effectiveness of differ-
ent airways clearance devices or techniques and their
cost-effectiveness, but especially to establish their
acceptability in order to long-term home use.
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